Maraviroc Selzentry UK-427857 CAS:376348-65-1

CAS NO: 376348-65-1
Maraviroc Selzentry UK-427857 CAS:376348-65-1
Description Review
Description

Maraviroc, also known as UK-427857 or CAS: 376348-65-1, is a prescription medication used to treat Human Immunodeficiency Virus (HIV) infection. In this article, we will discuss everything you need to know about maraviroc, including its chemical structure, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion.

Introduction: Maraviroc is a medication that belongs to a class of drugs called entry inhibitors. It works by blocking the CCR5 co-receptor on the surface of CD4+ T-cells, which prevents the virus from entering and infecting these cells. This action ultimately reduces HIV replication, slows disease progression, and improves immune function.

Chemical Name: The chemical name for maraviroc is 4,4-difluoro-N-{(1S)-3-[(1-{3-[(1-methyl-1H-pyrazol-5-yl)amino]-4-methylpentyl}carbamoyl)-2-(3-pyridyl) cyclopropyl] amino}-3-(3-pyridyl)benzamide.

Molecular Formula: The molecular formula of Maraviroc is C29H41F2N5O.

Formula Weight: The formula weight of Maraviroc is 513.68 g/mol.

CAS No: The CAS number for Maraviroc is 376348-65-1.

Top Ten Keywords from Google and Synonyms:

  1. HIV
  2. Antiretroviral
  3. Entry inhibitor
  4. CCR5 antagonist
  5. Tropism assay
  6. Viral load
  7. Immune function
  8. Fusion inhibitor
  9. Raltegravir
  10. Truvada

Synonyms: Selzentry, Celsentri

Health Benefits of Maraviroc: Maraviroc is primarily used to treat HIV infection in combination with other antiretroviral medications. It can reduce the viral load and slow down the progression of the disease. Additionally, it has been shown to improve immune function and reduce the risk of opportunistic infections.

Potential Effects: Apart from its main anti-HIV effects, Maraviroc has been found to have several other potential beneficial effects on various organs and systems in the body. Some of these effects include:

  • Anti-inflammatory effects: Maraviroc has been found to have anti-inflammatory properties, which may help reduce inflammation in the body.
  • Cardiovascular protection: Maraviroc has been reported to have cardiovascular protective effects, which may help reduce the risk of heart disease in people with HIV.
  • Neuroprotective effects: Maraviroc has been found to have neuroprotective properties, which may help protect against neurological damage caused by HIV.

Product Mechanism: Maraviroc works by binding to the CCR5 co-receptor on the surface of CD4+ T-cells, preventing the entry of the virus into these cells. As a result, the virus cannot replicate and spread throughout the body.

Safety: Maraviroc is generally safe when taken as prescribed by a healthcare provider. However, like all drugs, it may cause side effects in some people. Therefore, it is important to discuss any medical conditions or medications you are taking with your doctor before starting maraviroc. It should not be used during pregnancy or while breastfeeding.

Side Effects: Some of the common side effects associated with maraviroc use include diarrhea, nausea, headache, fatigue, and cough. Rare but serious side effects include allergic reactions, liver problems, and immune reconstitution syndrome.

Dosing Information: The recommended dose of maraviroc varies depending on the individual's condition, age, and other factors. It is usually taken twice daily, with or without food. It is important to take maraviroc exactly as prescribed by your healthcare provider.

Conclusion: Maraviroc is an entry inhibitor medication used to treat HIV infection. It works by blocking the CCR5 co-receptor on the surface of CD4+ T-cells, which prevents the virus from entering and infecting these cells. Apart from its main anti-HIV effects, maraviroc has been found to have several other potential beneficial effects on various organs and systems in the body. However, like all drugs, it may cause side effects in some people, so it is important to discuss any medical conditions or medications you are taking with your doctor before starting maraviroc. Overall, Maraviroc is an effective and safe medication for the treatment of HIV infection when used in combination with other antiretroviral medications

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code